Nicotinamide Riboside 250mg IV Drip

An intravenous infusion of 250mg nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+. NR is one of the most studied NAD+ precursors in longevity research, with the intravenous route offering direct systemic delivery that bypasses first-pass hepatic metabolism.

Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 that the body converts into NAD+ through a two-step enzymatic pathway involving nicotinamide riboside kinases (NRK1 and NRK2). As a NAD+ precursor, NR has attracted significant research attention in the longevity science community, with several human clinical trials demonstrating its ability to raise blood NAD+ levels when taken orally. The intravenous route potentially offers a more direct delivery path, although comparative bioavailability data between oral and IV NR administration is still emerging. The rationale for NR supplementation centres on the well-documented age-related decline in NAD+ levels and the downstream consequences for mitochondrial function, sirtuin activity, and DNA repair capacity. By providing the raw material for NAD+ biosynthesis, NR aims to support the body's own production rather than delivering the end-product directly — an approach that some researchers suggest may produce a more physiologically sustained elevation in NAD+ levels compared to direct NAD+ infusion. At EUR 400, this is IV Drip Milano's premium offering, reflecting the cost of pharmaceutical-grade NR and the specialist administration required. The drip is typically chosen by individuals already engaged in structured longevity protocols, those who have researched NAD+ biology and want to explore the precursor approach, or biohacking enthusiasts seeking the most advanced offerings in the IV therapy space. Administration is handled by the clinic's ICU/ER-trained nursing team with full clinical monitoring.